Application note: Improved RP-HPLC to analyse intact mAb’s
Posted: 11 March 2021 | Merck | No comments yet
A fast, high-resolution, and reproducible reverse phase HPLC method using the BIOshell™ A400 Protein C4 column to analyse the intact mAb Trastuzumab.
This application note demonstrates that the BIOshell™ A400 Protein C4 column, based on a wide-pore (400 Å) Fused-Core® particle design, is ideally suited for separating the intact therapeutic monoclonal antibody (mAb) Trastuzumab. The retention time, area precision, quantification, and robustness make this RP-HPLC method ideal for biopharma QC. The method can also be used to monitor degraded product created by heat stress, making it suitable for stability studies.
Related content from this organisation
- Moderna-Merck & Co cancer vaccine with Keytruda shows late-stage promise
- Raman-based PAT tool could advance continuous vaccine manufacturing
- Merck acquires JSR Life Sciences chromatography business
- MSD acquisition to accelerate first-in-class COPD drug
- Next drug patent cliff to challenge Big Pharma strategy
Related topics
Analytical techniques, Biopharmaceuticals, Formulation, Manufacturing, QA/QC, Research & Development (R&D)
